Sort 2 diabetes is related to elevated threat of kidney stones, however some types of therapy for this situation may take pleasure in decreasing threat of kidney stones. In a examine led by investigators from Mass Common Brigham, researchers discovered that there was an affiliation between the usage of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a decrease threat of growing kidney stones. Their findings are reported in JAMA Inside Medication.
Charges of kidney stones are on the rise in the USA and world wide. Sort 2 diabetes is related to elevated threat of kidney stones, however some types of therapy for this situation may take pleasure in decreasing threat of kidney stones. In a examine led by investigators from Mass Common Brigham, researchers discovered that there was an affiliation between the usage of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a decrease threat of growing kidney stones. Their findings are reported in JAMA Inside Medication.
Researchers from Brigham and Girls’s Hospital and Massachusetts Common Hospital, founding members of the Mass Common Brigham healthcare system, labored collectively to conduct the evaluation. The examine included knowledge from three nationwide databases of sufferers with sort 2 diabetes who had been seen in routine scientific apply. The group analyzed info from 716,406 adults with sort 2 diabetes who had began taking an SGLT2 inhibitor or two different lessons of diabetes drugs generally known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors. Sufferers who started taking SGLT2 inhibitors had a 30 % decrease threat of growing kidney stones than these taking GLP1 agonists and a couple of 25 % decrease threat than these taking DPP4 inhibitors. The findings had been constant throughout intercourse, race/ethnicity, historical past of continual kidney illness and weight problems.
“Our findings might assist inform scientific resolution making for sufferers with diabetes who’re in danger for growing kidney stones,” mentioned corresponding creator Julie Paik, MD, ScD, MPH, of the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Renal (Kidney) Medication at Brigham and Girls’s Hospital.
